ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2982

Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up

Pomme Poppelaars1, Lilian van Tuyl2 and Maarten Boers1,3, 1Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, 3Epidemiology & Biostatistics, Epidemiology & Biostatistics | VU University Medical Center, Netherlands, Amsterdam, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: death, Epidemiologic methods, modifiable risk, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, October 24, 2018

Session Title: 6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

ACR abstract

Background/Purpose:

Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more than a decade of follow up. The COBRA (COmbinatietherapie Bij Rheumatoide Artritis) trial showed long-term effectiveness of combination therapy of early RA without undue harm [1]. After 11 years of follow up, patients with COBRA treatment had numerically lower mortality compared to patients with sulphasalazine (SSZ) monotherapy [2]. We now present mortality in the COBRA trial cohort after 23 years compared to the general population and explore early predictive factors.

Methods:

In the COBRA trial, patients with early RA (median disease duration, 4 months) were treated with SSZ monotherapy (n=79) or a combination of SSZ, low-dose methotrexate and initially high, step-down prednisolone (COBRA, n=76). We investigated mortality in the COBRA cohort through the Dutch state registry for mortality (Centrum van Familiegeschiedenis). We compared the mortality in this cohort to a reference sample of the general population in the Netherlands matched for age and gender (Statistics Netherlands). The Standardized Mortality Ratio (SMR) compared the trial groups with the general population. We explored the following early predictive factors for mortality through forward stepwise Cox regression: smoking, treatment, disease duration (according to 3 definitions), disease activity score (DAS-44) and 16-week change; Health assessment questionnaire; rheumatoid factor (ACPA not available at that time); Sharp van der Heijde damage score and change at 28 and 56 weeks; HLA-DR1-4.

Results:

Follow up was nearly complete (154/155 patients). Duration of follow up was mean 23 (in patients alive, range 22-24) years. In total 44 patients died (28%, SMR = 0.80 [95%CI: 0.59-1.06]); 20 of 75 COBRA patients (27%, SMR 0.75; [0.47-1.14]) and 24 of 79 SSZ patients (30%, SMR 0.85 [0.56-1.25]); the difference in mortality was not significant (p=0.61). In the general population reference sample (n=154) 55 people (36%) died. The positive trend for COBRA over SSZ decreased over time (Figure). 5 factors were significantly associated with increased mortality hazard: damage progression at 28 weeks; high HAQ score; and absence of HLA-DR 2 or 3. Disease duration from start of complaints showed a nonlinear pattern.

Conclusion:

This is the first early RA (trial) cohort to show mortality similar to the general population after 23 years of follow up. In fact, mortality was numerically lower than expected. Some (but not all) predictive factors for disease severity were apparent. Our study confirms that early, intensive treatment of RA (that can include glucocorticoids) has long-term benefits, and strongly suggests these benefits include normalization of mortality.

References:

1. Boers M. Lancet 1997;350:309-18.

2. van Tuyl LH. Ann Rheum Dis 2010;69:807-12.


Disclosure: P. Poppelaars, None; L. van Tuyl, None; M. Boers, None.

To cite this abstract in AMA style:

Poppelaars P, van Tuyl L, Boers M. Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/normal-mortality-of-the-cobra-early-rheumatoid-arthritis-trial-cohort-after-23-years-follow-up/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/normal-mortality-of-the-cobra-early-rheumatoid-arthritis-trial-cohort-after-23-years-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences